Ii-Key-H5N1 vaccine

Ii-Key-H5N1 vaccine is an investigational **peptide vaccine** for prevention of avian influenza A H5N1 infection that uses the Ii-Key platform, in which an influenza H5N1 hemagglutinin-derived MHC class II epitope is linked to the invariant-chain Ii-Key motif to enhance peptide loading onto MHC class II molecules and amplify CD4 T-cell help. The approach is intended to increase the immunogenicity of short antigenic peptides and support downstream humoral and cellular immune responses against H5N1 influenza. Available public evidence indicates this was an early-stage influenza vaccine concept associated with Ii-Key platform developers including Generex Biotechnology and later YoufengBio platform materials; however, specific clinical product details such as finalized formulation, exact peptide sequence, adjuvant, manufacturer, and route for the exact Ii-Key-H5N1 vaccine are not well documented in accessible primary sources.

Other names

Ii-Key H5N1 vaccineIi-Key hybrid influenza vaccineIi-Key influenza A H5N1 peptide vaccine